Manage your formulary budget
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Diltiazem formulations and methods of treatment|
|Abstract:||A diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane surrounding the core and containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmaceutically acceptable film-forming, water soluble synthetic polymer. The number of layers in the membrane and the ratio of the water soluble to water insoluble polymer being effective to permit release of diltiazem from the pellet at a rate allowing controlled absorption thereof over a twelve hour period following oral administration. The pellet has a dissolution rate in vitro which when measured in a dissolution apparatus (Paddle) according to U.S. Pharmacopoeia XXI in 0.05 M KC1 at pH 7.0 results in not more than 35% of the total diltiazem being released after 2 hours of measurement. Not more than 80% of the total diltiazem is released after six hours of measurement and not less than 85% of the total diltiazem is released after 13 hours of measurement.|
|Inventor(s):||Geoghegan; Edward J. (Athlone, IE), Mulligan; Seamus (Gainesville, GA), Panoz; Donald E. (Tuckerstown, BM)|
|Assignee:||Elan Corporation, plc (Athlone, IE)|
|Filing Date:||May 19, 1993|
|Claims:||1. A method of controlling or preventing angina attacks or reducing the incidence of angina attacks in a subject suffering from angina pectoris, comprising administering to said subject on a once per 12 hour basis a dose effective to improve the blood supply and hence increase the oxygen supply in the myocardium of said subject throughout said 12 hour period, of a diltiazem containing controlled absorption pellet formulation, said pellet comprising a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, said core surrounded by a multi-layered polymeric membrane, each layer containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmacetutically acceptable film-forming water soluble synthetic polymer, the ratio of said diltiazem to organic acid and the ratio of water insoluble polymer to water soluble polymer being effective to provide peak myocardium oxygenating levels int eh blood 4 to 12 hours following administration. |
2. The method of claim 1 wherein the ratio of the diltiazem component and the organic acid is from about 19:1 to 1:1.
3. The method of claim 1 wherein a plurality of pellets are administered in capsule form.
4. The method of claim 1 wherein a plurality of pellets are administered in tablet form.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.